Archimedic

Speed vs. Certainty in MedTech Which one really drives success? Most startups chase speed: - Build a minimum viable product - Rush to design freeze - Push through V&V - Hire sales rep and scale But speed often leads to the redo loop—and the redo loop takes far longer than a path focused on certainty. What does certainty look like? - A feedback-driven approach - Pressure-testing problem statements - Deeply understanding customer needs - Consistently gathering user feedback - Seeking out the "no" from stakeholders Before making speed your priority, consider what you might be sacrificing. In MedTech, certainty is always the better bet. #medtech #medicaldevices #mvp Archimedic

The stability of an ampoule. With the usability of a prefilled syringe. Meet Ampulis—the drug delivery tech we're building out in the open. Who is it for? 1. HCPs delivering anesthesia drugs: Most perioperative anesthesia drugs are pre-prepared by hospital pharmacies. But in 5% of cases, emergency anesthetics are needed quickly. Anesthetics often require ampoule stability due to volatility. When every second counts, ease of use and speed are essential. 2. HCPs and patients administering oncology drugs: Oncology drugs are cytotoxic, posing safety challenges for healthcare professionals. As more treatments move from hospitals to homes, patients and providers need a safe, reliable delivery device for these potent drugs. Got questions or comments? Drop them below—we’d love your feedback! #pharma #drugdelivery #medtech Archimedic

Did you miss this one? The Value Analysis Whisperer delivered. Lucky for you, we've got a recording. Link below. Medtech ??'s inside. Mark Copeland Archimedic

Looking forward to a great conference at PODD in Boston. Amazed at how much pioneering work is taking place in drug delivery. if you are here, please drop by our booth to say hello. Jorge J. Capurro Rightley McConnell Archimedic

Problem obsession: What's better - a mediocre solution to a real problem or an amazing solution to a nonexistent problem? And who gets to define the problem -- you or paying customers? That's where I'm at with the drug delivery spinoff business. We have ideas galore, patents filed, prototypes. Internally, we think they're great. But we aren't the real customers. Our opinion on the problem doesn't really matter. So, I'm spending a lot of time obsessing over problems with target users and customers. > Who's the customer? > What's the real problem? > Is there willingness to pay? Basic stuff. And sounds so simple. (It's not..) Nailing the problem is so much more important than nailing the solution. #pharma #drugdelivery #medicaldevices

Post-Market Purgatory: Where most of #medtech meets the end. It's where you're cleared to sell, but nobody's buying. It's where #valueanalysis committees have the final say. Want to know how to avoid post-market purgatory? Join LinkedIn LIVE on Thurs (10/24) from 12-1pm Eastern to learn about this exact topic.

#Pharma Jargon: Extractables Leachables Particulate Contaminants Foreign Matter ... All this jargon was blending together for me. So, I talked to some people more knowledgeable on the subject to get some insights and perspective. In this brief video, I'll try to unpack some of this jargon and help you understand what these terms mean, how they relate to one another, and why they're important when developing new drug delivery devices. Any other jargon that needs to be unpacked? #drugdelivery #biologics #medicaldevices

What’s the hardest part of MedTech? Hint -- it has nothing to do with the Tech. >> It’s getting hospitals to buy. Hope you can join Copeland and myself break open the black box around #valueanalysis. Not only will we reveal the secrets, more importantly we’ll discuss what you can do about them – BEFORE you freeze your design.. Please join us on 10/24 from 12-1PM EST for this must-attend MedTech event. #medicaldevices #medtech #digitalhealth Archimedic

How to land on the right Need Statement? Here's how Jorge and I break it down for our new #drugdelivery device. But first.. Feedback received from Edwina and Joris suggested.. ?? Gotta define WHO it's for? An important detail, right? Here's our WHO: Healthcare providers (HCPs) delivering drugs stored in vials. What are the problems? Lots. So, to help us think holistically through the problems, we're looking through the following 3 axes: Axis 1?? - Technical - Coring of vial septum that results in injected particulate - Extractables & leachables from materials contacting drug Axis 2?? - Regulatory - Performing tests to demonstrate safety/effectiveness - Meeting consensus standards Axis 3?? - Marketing - Inconvenience of multiple steps - Confusion of what needle / syringe to use with vial Those are just some of the problems / challenges associated with HCPs accessing and delivering drugs stored in vials. But the centerpiece of this analysis is -- injected particulate -- which can be a big problem for patients. Turns out that many of the problems we've listed directly contribute to this injected particulate. So, we've landed on the following Need Statement ?? "A low-cost drug delivery solution for healthcare providers that reduces the risk of injected foreign particulate." That's where we're aiming (for now).. Got some ?? feedback ?? for us? Drop it in the Comments. And big thanks for all the comments Mark, Ulrich, Drew, Mark, Penny, Zikria, Ramses, Edwina, Joris, and Scott from the last post. Keep it coming please! Archimedic #pharma #drugdelivery #medtech

What's the problem we're trying to solve? Looking for your feedback here.. PROBLEM STATEMENT: Pharma prefers pre-filled syringes for usability but defaults to vials for drug stability. #Pharma - do you see this the same way? #Entrepreneurs - how could this problem statement be more clear? Weigh-in below. Thanks!